Ads
related to: tyrosine kinase inhibitor therapy- Efficacy & Safety Data
Learn More About The
Efficacy & Safety Data For ENHERTU.
- Downloadable Resources
Access ENHERTU Downloadable
Resources For Your Patients.
- ENHERTU Clinical Data
Visit To View Important ENHERTU
Clinical Data For Your Practice.
- Register For Updates
Register Today To Receive
Updates on ENHERTU. HCP Site.
- ENHERTU Dosing
Find ENHERTU Dosing & Admin
Resources For Your Practice.
- ENHERTU Resources
Find Helpful ENHERTU Resources
For Your Practice.
- Efficacy & Safety Data
Search results
Ponatinib superior to imatinib in Ph+ ALL - Nature Reviews Clinical Oncology
Nature· 2 days agoBCR–ABL1 tyrosine kinase inhibitors, in combination with chemotherapy and/or steroids, are the standard-of-care therapy</ ...
Drug resistance discovery could 'move the field forward' for breast cancer treatment
Medical Xpress· 9 hours agoAdditionally, the research team tested a promising drug in combination with an existing therapy that...
Eisai Showcases Oncology Portfolio and Pipeline at ASCO 2024
FOX 23 News Albany· 7 days agoNotable data include an oral presentation on biomarker analyses from the pivotal Phase 3 CLEAR (Study 307)/KEYNOTE-581 trial (NCT02811861), which evaluated lenvatinib (LENVIMA®), the orally ...
ASCO 2024 | Ascentage Pharma Releases Latest Results from Multiple Clinical Studies of Its Lead Drug...
WKRN Nashville· 6 days agoAscentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that its ...
Jaguar Health to Initiate Commercial Footprint in Cancer Supportive Care at American Society of...
Digital Journal· 6 days agoOral mucositis, also called "chemo mouth," has emerged as the most significant adverse event in oncology according to a National Comprehensive Cancer Network task forceTop line results imminent ...
Small Business - Shelby County Reporter | Shelby County Reporter
The Shelby County Reporter· 6 days agoPreliminary data from CLN-619 in combination with checkpoint inhibitor pembrolizumab show objective responses in patients with tumor types that are typically unresponsive to pembrolizumab, such as non-small cell lung cancer (NSCLC) with oncogenic
Exploring the pathways of drug repurposing and Panax ginseng treatment mechanisms in chronic heart...
Nature· 3 days agoChronic Heart Failure (CHF) is a significant global public health issue, with high mortality and morbidity rates and associated costs. Disease modules, which are collections of disease-related ...
Cogent Biosciences Appoints Cole Pinnow as Chief Commercial Officer - Cogent Biosciences...
Benzinga· 6 days agoCogent Biosciences, Inc. COGT, a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the appointment of Cole Pinnow as Chief Commercial ...
Ads
related to: tyrosine kinase inhibitor therapy